Sun Xiao-Yi, Wei Li-Li, Chen Hai-Liang, Liang Wen-Quan
Institute of Pharmaceutics, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou 310058, China.
Yao Xue Xue Bao. 2009 Aug;44(8):838-44.
Modern drug delivery system demands high therapeutic efficacy and low toxicity which depends on efficient intracellular transportation of therapeutics to specific organisms, cells, even targeted organelles such as cytosol, nucleus, mitochondria, lysosome and endoplasmic reticulum. Intracellular barriers which prevent drug molecules accessing to their targets mainly include cell membrane, lysosomal degradation and the endomembrane system. Nanocarriers can preserve the bioactivities of protein, enzyme and DNA, and also they are easy to be modified and functionalized. In this paper, we summarized the intracellular fate of nanocarriers, especially how to bypass intracellular barriers and then target cytosol, nucleus, mitochondria, lysosome and endoplasmic reticulum by pharmaceutical modifications.
现代药物递送系统要求具有高治疗效果和低毒性,这取决于治疗药物能否有效地在细胞内转运至特定的生物体、细胞,甚至靶向细胞器,如细胞质、细胞核、线粒体、溶酶体和内质网。阻碍药物分子到达靶点的细胞内屏障主要包括细胞膜、溶酶体降解和内膜系统。纳米载体能够保留蛋白质、酶和DNA的生物活性,并且易于进行修饰和功能化。在本文中,我们总结了纳米载体在细胞内的命运,尤其是如何通过药物修饰绕过细胞内屏障,进而靶向细胞质、细胞核、线粒体、溶酶体和内质网。